C6orf150 Inhibitors
C6orf150, also known as Interferon-Induced Protein 35 (IFI35), is a gene that encodes a protein involved in the cellular response to interferons, particularly in the context of antiviral defense mechanisms. The protein plays a significant role in modulating the innate immune response against viral infections by participating in the interferon signaling pathway, which leads to the activation of genes that inhibit viral replication and spread. The expression of C6orf150 is upregulated in response to viral infections, suggesting its importance in the host's defense mechanism against pathogens. Its function involves complex interactions with other proteins within the interferon pathway, contributing to the regulation of immune responses. Understanding the role of C6orf150 in the interferon signaling pathway is crucial for elucidating the mechanisms of antiviral defense and the broader implications of interferon-mediated immune modulation.
The inhibition of C6orf150, or IFI35, involves mechanisms that disrupt its expression or interfere with its function within the interferon signaling pathway. Inhibition can be achieved at the genetic level, through strategies such as RNA interference (RNAi) that target the mRNA of C6orf150, leading to a decrease in protein synthesis. This approach directly impacts the availability of C6orf150 for participation in immune response pathways. Additionally, small molecules or peptides that interfere with the protein-protein interactions involving C6orf150 can also serve as inhibitors, thereby disrupting its role in signal transduction processes associated with the antiviral response. Such inhibition does not necessarily require direct interaction with the protein's active site but may involve altering its structure or stability, impacting its ability to interact with other components of the interferon signaling pathway. Investigating the inhibition of C6orf150 provides insights into the modulation of immune responses and the ability to influence the outcome of viral infections, emphasizing the importance of this protein in antiviral defense mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits CGAS indirectly by suppressing the activity of various protein kinases, including PKC and PKA. These kinases are crucial in the regulation of cellular signaling pathways. By targeting these kinases, staurosporine disrupts the balance of signaling cascades, leading to a downstream effect on the cellular processes involving CGAS. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB-203580 is a p38 MAPK inhibitor that indirectly influences CGAS by targeting the MAPK signaling pathway. By inhibiting p38 MAPK, SB-203580 disrupts the normal signaling cascade, affecting downstream events associated with CGAS regulation. This compound represents a potential indirect inhibitor by modulating the cellular pathways connected to CGAS activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly inhibits CGAS by disrupting the PI3K/AKT signaling pathway. This pathway is involved in various cellular processes, including immune responses. Inhibiting PI3K with LY294002 can impact the downstream events that intersect with CGAS, thereby influencing its regulation and activity indirectly. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly modulates CGAS by targeting the NF-κB signaling pathway. NF-κB is a key regulator of immune and inflammatory responses. By inhibiting NF-κB, BAY 11-7082 disrupts the normal signaling events that intersect with CGAS, leading to an indirect modulation of CGAS activity through alterations in the cellular inflammatory response. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences CGAS by disrupting the PI3K signaling pathway. PI3K is involved in various cellular processes, including immune regulation. Inhibiting PI3K with Wortmannin can impact downstream events that intersect with CGAS, leading to an indirect modulation of CGAS activity through alterations in the cellular immune response. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits CGAS by disrupting the mTOR signaling pathway. mTOR is a central regulator of cellular processes, including autophagy and immune responses. By inhibiting mTOR, Rapamycin can impact downstream events that intersect with CGAS, leading to an indirect modulation of CGAS activity through alterations in the cellular processes regulated by mTOR. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly influences CGAS by targeting the JNK signaling pathway. JNK is involved in cellular stress responses and immune regulation. By inhibiting JNK, SP600125 disrupts the normal signaling cascade, affecting downstream events associated with CGAS regulation. This compound represents a potential indirect inhibitor by modulating the cellular pathways connected to CGAS activity. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 indirectly influences CGAS by modulating the NF-κB signaling pathway. As an IKK inhibitor, SP2509 disrupts the normal activation of NF-κB, a key regulator of immune responses. By inhibiting IKK and subsequently NF-κB, SP2509 affects downstream events associated with CGAS regulation, leading to an indirect modulation of CGAS activity through alterations in the cellular inflammatory response. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $66.00 $273.00 | 3 | |
LY303511, an inactive analog of LY294002, indirectly inhibits CGAS by disrupting the PI3K/AKT signaling pathway. Similar to LY294002, LY303511 impacts downstream events involving CGAS regulation by inhibiting PI3K. This compound serves as an indirect inhibitor, influencing CGAS activity through alterations in the cellular processes regulated by the PI3K/AKT signaling pathway. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 is a JAK2 inhibitor that indirectly affects CGAS by modulating the JAK/STAT signaling pathway. By inhibiting JAK2, VX-745 disrupts the normal signaling cascade, affecting downstream events associated with CGAS regulation. This compound represents a potential indirect inhibitor by modulating the cellular pathways connected to CGAS activity. | ||||||